Bayer subsidiary BlueRock Therapeutics has entered into an agreement with BioCardia that would combine the two companies’ technologies to treat heart failure.

The companies plan to use BlueRock’s cell therapy product candidates with BioCardia’s minimally invasive biotherapeutic delivery products. No specific product candidates were named, however.

The agreement includes an option for a nonexclusive worldwide license to BioCardia’s biotherapeutic delivery product candidates for certain cell types for cardiac indications.

BioCardia will receive an undisclosed upfront payment, a portion of which is for biotherapeutic delivery products and support services.